Over the past two decades, our team has built a reputation of trust, integrity and deep expertise in healthcare.

Adam Fine is Co-Founder, General Partner, and CEO of Windham Capital Partners. Adam is currently a Board Director at GlySens, HelpAround, Neuspera, SubjectWell, Andros, and Valera, and Board Observer to Nuvaira, Chromacode, and Upward Health. Prior to Windham, Adam was VP & GM at I-many, Inc., an enterprise software company. Before joining I-many, Adam was a New Business Development Analyst at Cordis Corporation, a Johnson & Johnson company focused on interventional vascular devices such as stents. In that capacity, Adam worked on a range of licenses, acquisitions, divestments, as well as strategic investments with Johnson & Johnson Development Corporation (JJDC), J&J’s strategic venture arm. Prior to J&J, Adam was a research analyst at Coopers & Lybrand’s Integrated Healthcare Consulting practice. Adam received his BA and graduated cum laude with distinction from Boston University and received his MBA from New York University. Adam lives on the Upper West Side of Manhattan with his wife and three children.

David joined Windham Capital Partners in 2023 as a Managing Partner helping to oversee all aspects of the fund. Most recently, David served as a Partner with Providence Ventures where he was actively involved in driving new strategic growth initiatives for Providence, helping to shape the future of one of America's largest comprehensive health care organizations.

As an investor, board member, and advisor, David has helped support talented healthcare entrepreneurs realize over $1 billion in value. Over his career, he has led or co-led investments in Bolder Surgical (acquired by Hologic), Veran Medical (acquired by Olympus), TissueTech (acquired), Advanced Practice Strategies (acquired by Relias Learning), SurgiQuest (acquired by Conmed Corp), TailorMed, MacroHealth, OrthAlign, and NICO Corporation (acquired by Stryker Corporation). Additionally, David currently or previously served on the Board of Directors of TailorMed, DexCare, Wildflower Health, Veran Medical, and AVIA Health.

‍

Earlier in his career, David served as a Principal with RC Capital and as President and Board Member of Mid-America Health Investors Network (MHIN), one of the Country’s largest industry groups, where he represented over 60 active healthcare funds with offices spread throughout Middle America.

‍

David graduated from Indiana University’s Kelley School of Business and received his MBA with a concentration in finance from Xavier University’s Williams College of Business.

‍

David and his family remain activein the Seattle and Cincinnati communities supporting various initiatives targeting behavioral health, education and youth programs, veteran affairs, and medical research programs.

Roger Fine is a co-founder and Chairman of Windham Capital Partners. Roger retired as corporate vice president and general counsel of Johnson & Johnson (J&J) after a 30-year career with the company. He served as a member of the J&J Executive Committee for 15 years. Roger is the chairman of the board of trustees of the Robert Wood Johnson Foundation, the 3rd largest foundation in the U.S. and the largest foundation in the world devoted to healthcare. He is also chairman of the board of trustees of the Child Health Institute of New Jersey. Roger currently serves on the Business Advisory Board of Healthpoint Capital, a private equity fund in New York. He is also chairman of the Foundation Venture Capital Group, an in-house VC fund focused on commercializing discoveries made by scientific faculty at the Rutgers Medical School. Roger graduated from Columbia University and earned his law degree from New York University School of Law.

Joe Proto became Chairman and Chief Executive Officer of Transactis Inc. in 2007, after nearly three decades in the billing and payments industry as a senior executive and successful entrepreneur. Prior to Transactis, he launched REMITCO, a remittance processing company, which was acquired in 2000 by First Data Corp, as well as Financial Telesis (CashFlex), which was acquired in 1992 by CoreStates, now part of Wells Fargo. Joe recently joined the Board of Directors of BillMyParents and is also an LP and Advisor in Metamorphic Ventures (focused on transactional media). Joe is a member of various financial services associations and has been a frequent speaker at conferences in the payments industry.

Sarah is a Vice President at Windham Capital Partners where she is responsible for sourcing, due diligence, and supporting our portfolio companies after investment. Prior to joining Windham, Sarah was an Operations Manager at Particle Health, a NYC-based digital health startup. Sarah's prior experience in venture capital includes her time at Healthy Ventures, where she was a research analyst, and her time at Red Bear Angels, a Cornell-affiliated angel investment group. Sarah received her BS and MBA from Cornell University through an accelerated BS/MBA program, where she graduated with distinction.

Kaylin Collins is the Operations Associate at Windham Capital Partners. Prior to Windham, Kaylin was the Office Manager and Executive Assistant at Interior Marketing Group, a luxury real estate design and marketing firm. Kaylin directly supported the CEO and executive management team. Kaylin received her BA from the University of Hartford in Hartford, CT.

Jason is the Founder of and Chief Solutions Officer for Helgerson Solutions Group, a health care consultancy firm focused on helping organizations successfully transition to a value based world. HSG works with private companies, governments and non-profit organization that need assistance in implementing value-based payment approaches and new care models that will lead to improved patient outcomes and lower overall costs. HSG is also a trusted advisor for private equity and venture capital firms as they look for new investment opportunities and work with companies to drive growth and profitability.Prior to founding HSG, Jason was New York’s Medicaid Director. Jason ran the $70 billion program for over 7 years and was recognized as one of the nation’s most effective healthcare leaders. Prior to New York, Jason was Wisconsin’s Medicaid Director where he lead the state’s nationally recognized Badgercare Plus program. When Jason left public service and founded HSG he was the nation’s longest standing Medicaid Director.

Alistair Erskine, MD is Chief Digital Health Officer of Emory Healthcare and former Chief Digital Health Officer at Mass General Brigham. Prior to Mass General Brigham, Dr. Erskine served as Chief Informatics Officer at the Geisinger Health System. Dr. Erskine led the Division of Informatics which engaged staff in the design and configuration of Geisinger’s clinical information systems and evolved Geisinger’s facilities to take advantage of ultramodern technologies. Prior to Geisinger, Dr. Erskine was Associate Dean of Medical Informatics at Virginia Commonwealth University and was member of the Board for the 650-physician Medical College of Physician practice plan. He was appointed to the Virginia Governor’s Health Information Technology Commission by Executive Order and was a voting member of the Health Information Technology Standards Committee. Dr. Erskine presents and publishes on the topic of clinical transformation in peer-reviewed literature. Dr. Erskine trained at Brown University and Virginia Commonwealth University Health System and is triple Board-Certified in Internal Medicine, Clinical Informatics and Pediatrics. He has been practicing hospital medicine for 15 years. He is currently engaged in a two-year program with MIT Sloan School of Management, with a specialization in Business Analytics and Artificial Intelligence. He earned his MBA from the MIT Sloan School of Management, with a specialization in Business Analytics and Artificial Intelligence

Deneen Vojta, MD is an Executive Vice President for Research and Development at UnitedHealth Group, where she leads Global Research and Development. Prior to UnitedHealth, Dr. Vojta was the Founder and CEO of MYnetico / Alliance Health Solutions, as well as the Chief Medical Officer at Health Partners and Frankford Health. Dr. Vojta has served as a board member of non-profit health care institutions and earned numerous federal and foundation grants to investigate complex health care concerns. She is widely published and frequently invited to speak on a number of health issues. Dr. Vojta received her BS in Behavioral Neurosciences at the University of Pittsburgh, and an MD from Temple University School of Medicine

Kush Mody is an Associate at Windham Capital Partners. Prior to Windham, Kush was a venture associate at the Columbia Lab-to-Market Accelerator and an intern in the emergency, trauma, and acute care unit at World Health Organization. Previously, he has also served as VP of Expansion at Sling Health and built an app to help emergency physicians better assess children with potential cervical spine injuries. Kush has conducted clinical research primarily related to orthopaedic surgery and has been published numerous times in leading journals. Currently, Kush is in his final year of an accelerated 7-year BS/MD program at Drexel University and pursuing an MBA at Columbia Business School.

Lorne Taichman is Director, Science & Technology at Windham Capital Partners.  Lorne has an MD degree from the University of Toronto and a PhD in Molecular Biology from the University of Wisconsin. Lorne is a professor emeritus at Stony Brook University where he directed a medical research laboratory for 30 years. His field of study was stem cells and gene and cell therapy. He has authored over 60 peer-reviewed publications and, in addition, was the recipient of an NIH MERIT award. In 2000, Lorne spent a sabbatical year at Johnson & Johnson’s Corporate Office of Science and Technology where he evaluated emerging technologies. Lorne remained a part-time consultant to COSAT and in 2007 he left the University to join Windham. As Windham’s Director of Science & Technology, Lorne assists in locating new technologies for our review and in critically assessing the opportunity they present.